Your browser doesn't support javascript.
loading
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Haas, M; Siveke, J T; Schenk, M; Lerch, M M; Caca, K; Freiberg-Richter, J; Fischer von Weikersthal, L; Kullmann, F; Reinacher-Schick, A; Fuchs, M; Kanzler, S; Kunzmann, V; Ettrich, T J; Kruger, S; Westphalen, C B; Held, S; Heinemann, V; Boeck, S.
Afiliación
  • Haas M; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. Electronic address: michael.haas@med.lmu.de.
  • Siveke JT; 2nd Medical Department, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany; Division of Solid Tumor Translational Oncology (DKTK, Partner Site Essen), West German Cancer Center, Univ
  • Schenk M; Department of Haematology and Oncology, Hospital Barmherzige Brüder, Regensburg, Germany.
  • Lerch MM; Department of Medicine A, Universitätsmedizin Greifswald, Ernst-Moritz-Arndt University, Greifswald, Germany.
  • Caca K; Department of Internal Medicine I, Klinikum Ludwigsburg, Ludwigsburg, Germany.
  • Freiberg-Richter J; Practice for Haematology and Oncology, Dresden, Germany.
  • Fischer von Weikersthal L; Department of Oncology, Gesundheitszentrum St. Marien, Amberg, Germany.
  • Kullmann F; Department of Medicine I, Klinikum Weiden, Weiden, Germany.
  • Reinacher-Schick A; Department of Haematology and Oncology, St. Josef-Hospital, Ruhr University, Bochum, Germany.
  • Fuchs M; Department of Gastroenterology, Hepatology and Gastrointestinal Oncology, Klinikum Bogenhausen, Munich, Germany.
  • Kanzler S; Department of Internal Medicine II, Leopoldina Krankenhaus Schweinfurt, Schweinfurt, Germany.
  • Kunzmann V; Department of Medical Oncology, University Hospital of Wuerzburg, Wuerzburg, Germany.
  • Ettrich TJ; Department of Internal Medicine I, University of Ulm, Ulm, Germany.
  • Kruger S; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Westphalen CB; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Held S; ClinAssess GmbH, Leverkusen, Germany.
  • Heinemann V; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
  • Boeck S; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Eur J Cancer ; 94: 95-103, 2018 05.
Article en En | MEDLINE | ID: mdl-29549862
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Ductal Pancreático Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Ductal Pancreático Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Cancer Año: 2018 Tipo del documento: Article